SCHEMBL4086557

SCHEMBL4086557

CCOC(=O)c1c(NC(=O)C2(c3ccccc3)CC3CCC2C3)sc2c1CCOC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 9/20 0.49
CNR1 P21554 2/20 0.49
PDE4D Q08499 1/20 0.47
TLR2 O60603 4/20 0.45
CXCR2 P25025 1/20 0.44
NPSR1 Q6W5P4 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 3/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 1/20 0.44
ALOX12 P18054 1/20 0.44
TP53 P04637 1/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
PTGER2 P43116 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094523 0.84 CNR2 (0.54) CNR2CNR1ALDH1A1HSD17B10MAPT
SCHEMBL4085480 0.80 PDE4D (0.55) CNR2PDE4DTLR2CXCR2NPSR1
SCHEMBL4084444 0.80 CNR2 (0.75) CNR2CNR1ALDH1A1HSD17B10MAPT
SCHEMBL4080042 0.79 CNR2 (0.76) CNR2CNR1ALDH1A1HSD17B10MAPT
SCHEMBL4090895 0.79 TLR2 (0.55) CNR2PDE4DTLR2CXCR2NPSR1
SCHEMBL4081101 0.77 CNR2 (0.73) CNR2CNR1ALDH1A1HSD17B10MAPT
SCHEMBL5450569 0.74 KMT2A (0.69) CNR2CNR1ALDH1A1HSD17B10MAPT
SCHEMBL4080908 0.74 TLR2 (0.50) CNR2CNR1PDE4DTLR2NPSR1
SCHEMBL14300777 0.74 KMT2A (0.51) CNR2CNR1NPSR1ALDH1A1HSD17B10
SCHEMBL4079863 0.73 CNR2 (0.72) CNR2CNR1ALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885CNR1 1/4885PDE4D 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.